Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.52% in after-hours trading on Wednesday, following the release of its fourth quarter and full year 2025 financial results.

The biopharmaceutical company reported a significant swing to profitability, with Q4 earnings of $0.13 per share compared to a loss of $0.09 per share in the same period last year, beating analyst estimates. Revenue for the quarter reached $129.5 million, representing an 81.5% year-over-year increase and also surpassing expectations. The strong performance was primarily driven by robust demand for the company's ZORYVE product, with net product revenue climbing 84% year-over-year.

Arcutis also raised its full-year 2026 net product revenue guidance to $480-$495 million, up from previous guidance of $455-$470 million. The company reported achieving positive operating cash flow in Q4 2025 and anticipates maintaining this trend going forward. Additional business updates included Medicare access beginning in January 2026 and recent FDA approval for ZORYVE cream 0.05% for atopic dermatitis in children ages 2 to 5.